Guangshengtang: Hepatitis B innovative treatment drug GST-HG131 II Phase clinical research summary report

GuangShengTang announced that its innovative drug for treating hepatitis B, GST-HG131, has completed Phase II clinical trials for chronic hepatitis B and has obtained the summary report of the Phase II clinical trial. The research results show that GST-HG131 tablets have a significant inhibitory effect on the hepatitis B surface antigen HBsAg in patients with chronic hepatitis B, and are well tolerated. GST-HG131 is an oral small molecule HBsAg inhibitor that can significantly suppress the expression of hepatitis B HBsAg, thereby exerting an antiviral effect. There is currently no similar product on the market globally. However, the company reminds investors to pay attention to the risks of long research and development cycles, high investment, and uncertainty in obtaining approval for innovative drugs.